Cancer
Skin Carcinoma
CI-CAN-00001511Explore in graph →
Top-level127 active trials2 approved drugs4 evidence items
- NCIt
- C4914
- ICD-10
- C44
- MeSH
- D000099313
Loading cancer entity…
Cancer
CI-CAN-00001511Explore in graph →
Clinical trials
389 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (52)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | not yet recruiting | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07740993 | A Single-Arm Study of Sintilimab and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland Carcinoma | not yet recruiting | Phase 2 | 25 | West China HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07715734 | Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma(CONTRAC-2) | not yet recruiting | Phase 2 | 22 | Washington University School of MedicineOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07455331 | Flash Radiotherapy for Skin Cancer(LANCE) | not yet recruiting | Phase 2 | 60 | Jules Bordet InstituteOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06418724 | Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma(NEOPECS) | not yet recruiting | Phase 2 | 27 | Melanoma and Skin Cancer Trials LimitedOTHER | 0 | Mar 27, 2026 | clinicaltrials |
| NCT07394244 | Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 38 | Fudan UniversityOTHER | 1 | Feb 6, 2026 | clinicaltrials |
Data updated 13 days agoSource updated Sep 17, 2026source: clinicaltrials